The intratumoral injection of STING agonists has shown great promise in preclinical cancer models and leads to an enhanced content of the tumor-intrinsic type I IFNs, increased C-X-C motif chemokine receptor 3–dependent (CXCR3-dependent) antitumor immunity, and increased survival (8). The gene discussed is STING1; the disease is neoplasm.